Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

BIBF 1120 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Study:

A Phase II Evaluation of BIBF 1120 (IND #) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Rationale:

BIBF 1120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

Purpose:

This phase II trial is studying the side effects and how well BIBF 1120 works in treating patients with recurrent or persistent endometrial cancer.

Study Status: Suspended

Recruiting:
n/a

Condition Intervention Phase
Endometrial Cancer Drug: nintedanib Phase 2

Verified by Gynecologic Oncology Group May, 2013

Sponsored by: Gynecologic Oncology Group
Information provided by: Gynecologic Oncology Group
ClinicalTrials.gov identifier: NCT01225887

Study Type: Interventional

Study Design: Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio 44111
United States

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Don S. Dizon, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site